Compare Amphastar Pharmaceuticals Inc (AMPH) vs Chevron Corp (CVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Chevron Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Chevron Corp trades at $196.26 (market cap $382.34B). The key difference: Chevron Corp is far larger — about 442.5× Amphastar Pharmaceuticals Inc's market cap, and Chevron Corp pays a 3.65% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CVX | |
|---|---|---|
Market Cap | $863.95M | $382.34B |
Sector | Health | Energy |
52-Week High | $30.81 | $211.14 |
52-Week Low | $16.87 | $146.72 |
Enterprise Value | $1.26B | $410.88B |
Volume | — | 9,807,834 |
Dividend Yield | — | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Chevron (CVX) trades at $196.66, up 5.41% today, reflecting strong momentum amid high oil prices. The stock shows bullish technical signals, with recent earnings beats and a consensus analyst price target of $214.25. Revenue declined to $184.43B in 2025, but net income margin held at 9.87%, with robust cash flow from operations of $33.94B. Recent news highlights strategic investments in Argentina and Greece, leveraging geopolitical tensions to boost production prospects.
Outlook is positive with oil price tailwinds and operational efficiency, but risks include volatile energy markets and debt increases. The stock offers a solid dividend yield and growth potential, supported by analyst bullishness, though investors should monitor execution on new projects and macroeconomic shifts affecting energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →
